Diabetes management (London, England)最新文献_第2页

2020 Market Analysis 2020年市场分析

Diabetes management (London, England) Pub Date : 2021-01-01 DOI: 10.37532/1758-1907.2021.11(5).229

O. Ojo

引用次数: 0

Identifying functional and non-functional specifications of a telehealth software application for diabetes mellitus 识别糖尿病远程医疗软件应用程序的功能和非功能规范

Diabetes management (London, England) Pub Date : 2021-01-01 DOI: 10.37532/1758-1907.2021.11(7).245-253

D. Folinas, Maria Tzilini Kyriakos Kazakos

{"title":"Identifying functional and non-functional specifications of a telehealth software application for diabetes mellitus","authors":"D. Folinas, Maria Tzilini Kyriakos Kazakos","doi":"10.37532/1758-1907.2021.11(7).245-253","DOIUrl":"https://doi.org/10.37532/1758-1907.2021.11(7).245-253","url":null,"abstract":"The study aims to identify and present the functional and non-functional technical and medical specifications of the software application that supports the clinical care of Diabetes Mellitus (DM) patients and maintain clinical information for monitoring, evaluation, and administration purposes in a research project titled cometech. The proposed software application belongs to the Electronic Health Management Information Systems (eHMIS) category that is designed to fulfill the need for an automated national health information management system. It is used for public health-related decision-making. Its main users are public policymakers, health officers, researchers, planning departments of health offices, eHMIS focal persons, data entry clerks, and many others ranging from health facility to federal management levels. The identification and analysis of the functional and non-functional requirements will help researchers to design and develop similar software applications that aim to introduce telehealth tools and services to achieve continuity of health care and to provide consultation and patient education (society awareness).","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":"11 1","pages":"245-253"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69923482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral medications 口服药物

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.4324/9780429326196-5

Janet Titchener

{"title":"Oral medications","authors":"Janet Titchener","doi":"10.4324/9780429326196-5","DOIUrl":"https://doi.org/10.4324/9780429326196-5","url":null,"abstract":"——— DOSAGE FORMS AND STRENGTHS ——— Injection: 2 mg/1.5 mL (1.34 mg/mL) available in: • Single-patient-use pen that delivers 0.25 mg or 0.5 mg per injection (3). • Single-patient-use pen that delivers 1 mg per injection (3). ——— CONTRAINDICATIONS ——— • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4). • Known hypersensitivity to OZEMPIC® or any of the product components (4). ——— WARNINGS AND PRECAUTIONS ——— • Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). • Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). • Never share an OZEMPIC® pen between patients, even if the needle is changed (5.4). • Hypoglycemia: When OZEMPIC® is used with an insulin secretagogue or insulin, consider lowering the dose of the secretagogue or insulin to reduce the risk of hypoglycemia (5.5). • Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions (5.6). • Hypersensitivity Reactions: Discontinue OZEMPIC® if suspected and promptly seek medical advice (5.7). ——— ADVERSE REACTIONS ——— The most common adverse reactions, reported in ≥5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc., at 1-888693-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.","PeriodicalId":89355,"journal":{"name":"Diabetes management (London, England)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42854706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pathophysiology of diabetes 糖尿病的病理生理学

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.4324/9780429326196-3

Janet Titchener

引用次数: 0

The physiology of glucose metabolism 葡萄糖代谢生理学葡萄糖代谢生理学

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.4324/9780429326196-2

Janet Titchener

引用次数: 0

Glycaemic management 血糖管理

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.4324/9780429326196-9

Janet Titchener

引用次数: 0

Surgical management of diabetes 糖尿病的外科治疗

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.4324/9780429326196-7

Janet Titchener

引用次数: 0

Making the diagnosis of diabetes 诊断糖尿病

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.4324/9780429326196-4

Janet Titchener

引用次数: 0

Lifestyle management 生活方式管理

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.4324/9780429326196-10

Janet Titchener

引用次数: 63

Introduction 介绍

Diabetes management (London, England) Pub Date : 2020-03-23 DOI: 10.1201/9780429326196-1

Janet Titchener

引用次数: 0